Masimo Corporation (MASI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Masimo Corporation stock (MASI) is currently trading at $178.09. Masimo Corporation PS ratio (Price-to-Sales) is 6.29. Analyst consensus price target for MASI is $178.60. WallStSmart rates MASI as Sell.
- MASI PE ratio analysis and historical PE chart
- MASI PS ratio (Price-to-Sales) history and trend
- MASI intrinsic value — DCF, Graham Number, EPV models
- MASI stock price prediction 2025 2026 2027 2028 2029 2030
- MASI fair value vs current price
- MASI insider transactions and insider buying
- Is MASI undervalued or overvalued?
- Masimo Corporation financial analysis — revenue, earnings, cash flow
- MASI Piotroski F-Score and Altman Z-Score
- MASI analyst price target and Smart Rating
Masimo Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Masimo Corporation (MASI) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, eps growth, institutional own.. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Masimo Corporation (MASI) Key Strengths (4)
Earnings per share surging 214.40% year-over-year
108.10% of shares held by major funds and institutions
Strong operational efficiency: $22 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Masimo Corporation (MASI) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Very expensive at 12.9x book value
Premium valuation at 6.3x annual revenue
Modest revenue growth at 8.20%
Supporting Valuation Data
Masimo Corporation (MASI) Detailed Analysis Report
Overall Assessment
This company scores 44/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 4 register as strengths (avg 8.8/10) while 6 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Operating Margin. Profitability is solid with Operating Margin at 21.60%. Growth metrics are encouraging with EPS Growth at 214.40%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, PEG Ratio. Some valuation metrics including PEG Ratio (4.83), Price/Sales (6.29), Price/Book (12.90) suggest expensive pricing. Growth concerns include Revenue Growth at 8.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -21.10%, Profit Margin at -26.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -21.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MASI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MASI's Price-to-Sales ratio of 6.29x sits near its historical average of 5.54x (69th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 57% below its historical high of 14.57x set in Nov 2020, and 204% above its historical low of 2.07x in Sep 2014. Over the past 12 months, the PS ratio has expanded from ~4.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Masimo Corporation (MASI) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Masimo Corporation is in a turnaround phase, with management focused on restoring profitability. Revenue reached 2.2B with 8% growth year-over-year. The company is currently unprofitable, posting a -26.1% profit margin.
Key Findings
Generating 53M in free cash flow and 61M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -26.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Masimo Corporation.
Bottom Line
Masimo Corporation is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Masimo Corporation(MASI)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Masimo Corporation develops, manufactures and markets non-invasive monitoring technologies and hospital automation solutions globally. The company is headquartered in Irvine, California.